MX2014006158A - Metodos para el tratamiento de artritis psoriasica (psa) utilizando antagonistas de il-17 y alelos con respuesta o sin respuesta a la psa. - Google Patents
Metodos para el tratamiento de artritis psoriasica (psa) utilizando antagonistas de il-17 y alelos con respuesta o sin respuesta a la psa.Info
- Publication number
- MX2014006158A MX2014006158A MX2014006158A MX2014006158A MX2014006158A MX 2014006158 A MX2014006158 A MX 2014006158A MX 2014006158 A MX2014006158 A MX 2014006158A MX 2014006158 A MX2014006158 A MX 2014006158A MX 2014006158 A MX2014006158 A MX 2014006158A
- Authority
- MX
- Mexico
- Prior art keywords
- psa
- response
- methods
- patient
- psoriatic arthritis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rehabilitation Therapy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IQ3702011 | 2011-11-21 | ||
| US201261624564P | 2012-04-16 | 2012-04-16 | |
| PCT/US2012/041310 WO2013077907A1 (en) | 2011-11-21 | 2012-06-07 | Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non- response alleles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014006158A true MX2014006158A (es) | 2014-06-19 |
Family
ID=48470189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014006158A MX2014006158A (es) | 2011-11-21 | 2012-06-07 | Metodos para el tratamiento de artritis psoriasica (psa) utilizando antagonistas de il-17 y alelos con respuesta o sin respuesta a la psa. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150064193A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2783014A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2015504430A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140097178A (cg-RX-API-DMAC7.html) |
| CN (1) | CN104011223A (cg-RX-API-DMAC7.html) |
| AR (1) | AR086907A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012341081B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014012101A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2856252A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2014006158A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2014125071A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013077907A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
| MX2013003681A (es) | 2010-10-01 | 2013-11-20 | Moderna Therapeutics Inc | Ácidos nucleicos manipulados y métodos de uso de los mismos. |
| EP4116325A1 (en) | 2010-11-05 | 2023-01-11 | Novartis AG | Methods of treating rheumatoid arthritis using il-17 antagonists |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| SMT202200355T1 (it) | 2011-12-16 | 2022-11-18 | Modernatx Inc | Composizioni di mrna modificato |
| EP2834260A4 (en) | 2012-04-02 | 2016-08-10 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| EP2922554B1 (en) | 2012-11-26 | 2022-02-23 | ModernaTX, Inc. | Terminally modified rna |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
| JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
| JP2017521479A (ja) | 2014-05-15 | 2017-08-03 | ラニ セラピューティクス， エルエルシー | ポリペプチドおよび／またはタンパク質を含む固体塊の薬学的組成物およびそれを製造するための方法 |
| US11548940B2 (en) | 2014-05-15 | 2023-01-10 | Rani Therapeutics, Llc | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| CA2960754A1 (en) * | 2014-09-10 | 2016-03-17 | Novartis Ag | Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients |
| AR103172A1 (es) | 2014-12-22 | 2017-04-19 | Novartis Ag | Reducción selectiva de residuos de cisteina en anticuerpos il-17 |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| TW201639596A (zh) * | 2015-01-24 | 2016-11-16 | 艾伯維有限公司 | 用於治療牛皮癬性關節炎之組合物及方法 |
| CA3001260A1 (en) | 2015-10-27 | 2017-05-04 | Ucb Biopharma Sprl | Methods of treatment using anti-il-17a/f antibodies |
| US11548941B2 (en) * | 2018-11-20 | 2023-01-10 | Janssen Biotech, Inc. | Safe and effective method of treating psoriasis with anti-IL-23 specific antibody |
| EP3980065A4 (en) * | 2019-06-04 | 2023-07-05 | Janssen Biotech, Inc. | SAFE AND EFFECTIVE METHOD OF TREATMENT OF PSORIAL ARTHRITIS WITH ANTI-IL23 SPECIFIC ANTIBODY |
| BR112022004941A2 (pt) * | 2019-09-20 | 2022-06-28 | Novartis Ag | Métodos para tratar doenças autoimunes com o uso de antagonistas de interleucina-17 (il-17) |
| US20220289834A1 (en) * | 2021-03-12 | 2022-09-15 | Janssen Biotech, Inc. | Method of Treating Psoriatic Arthritis Patients with Inadequate Response to TNF Therapy with Anti-IL23 Specific Antibody |
| KR20230156387A (ko) * | 2021-03-12 | 2023-11-14 | 얀센 바이오테크 인코포레이티드 | 항-il23 특이적 항체에 의해 건선성 관절염을 치료하는 안전하고 효과적인 방법 |
| CN114427001A (zh) * | 2022-01-29 | 2022-05-03 | 中日友好医院(中日友好临床医学研究所) | 基于78个snp位点评估阿达木单抗治疗银屑病有效性的试剂盒 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0417487D0 (en) * | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| GB0425569D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
| PT1963368E (pt) | 2005-12-13 | 2012-09-14 | Lilly Co Eli | Anticorpos anti-il-17 |
| WO2007117749A2 (en) | 2006-01-31 | 2007-10-18 | Novartis Ag | Il-17 antagonistic antibodies fpr treating cancer |
| GB0612928D0 (en) | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
| WO2008156865A2 (en) * | 2007-06-20 | 2008-12-24 | Schering Corporation | Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease |
| UA103499C2 (ru) | 2008-09-29 | 2013-10-25 | Рош Глікарт Аг | Антитело против интерлейкина-17 (ил-17) человека и его применение |
| EP2460007A4 (en) * | 2009-07-28 | 2013-06-19 | Janssen Biotech Inc | SERIAL MARKERS FOR THE PREDICTION OF CLINICAL RESPONSE TO ANTI-TNF ANTIBODIES IN PATIENTS WITH ARTHROPATHIC PSORIASIS |
| JP5537740B2 (ja) * | 2010-10-08 | 2014-07-02 | ノバルティス アーゲー | Ｉｌ−１７アンタゴニストを用いて乾癬を治療する方法 |
| WO2012082573A1 (en) * | 2010-12-13 | 2012-06-21 | Novartis Ag | Predictive methods and methods of treating arthritis using il-17 antagonists |
-
2012
- 2012-06-07 RU RU2014125071/10A patent/RU2014125071A/ru not_active Application Discontinuation
- 2012-06-07 KR KR1020147013196A patent/KR20140097178A/ko not_active Withdrawn
- 2012-06-07 EP EP12727081.7A patent/EP2783014A1/en not_active Withdrawn
- 2012-06-07 WO PCT/US2012/041310 patent/WO2013077907A1/en not_active Ceased
- 2012-06-07 JP JP2014542299A patent/JP2015504430A/ja active Pending
- 2012-06-07 AU AU2012341081A patent/AU2012341081B2/en not_active Ceased
- 2012-06-07 CN CN201280057295.5A patent/CN104011223A/zh active Pending
- 2012-06-07 CA CA2856252A patent/CA2856252A1/en not_active Abandoned
- 2012-06-07 MX MX2014006158A patent/MX2014006158A/es unknown
- 2012-06-07 US US14/358,504 patent/US20150064193A1/en not_active Abandoned
- 2012-06-07 BR BR112014012101A patent/BR112014012101A2/pt not_active IP Right Cessation
- 2012-06-11 AR ARP120102076A patent/AR086907A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014012101A2 (pt) | 2019-09-24 |
| WO2013077907A1 (en) | 2013-05-30 |
| AU2012341081A1 (en) | 2014-05-29 |
| US20150064193A1 (en) | 2015-03-05 |
| RU2014125071A (ru) | 2015-12-27 |
| EP2783014A1 (en) | 2014-10-01 |
| AR086907A1 (es) | 2014-01-29 |
| KR20140097178A (ko) | 2014-08-06 |
| AU2012341081B2 (en) | 2015-06-04 |
| CN104011223A (zh) | 2014-08-27 |
| JP2015504430A (ja) | 2015-02-12 |
| CA2856252A1 (en) | 2013-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014006158A (es) | Metodos para el tratamiento de artritis psoriasica (psa) utilizando antagonistas de il-17 y alelos con respuesta o sin respuesta a la psa. | |
| MX2009013410A (es) | Biomarcadores para predecir capacidad de respuesta anti-tnf o sin capacidad de respuesta. | |
| CY1122278T1 (el) | Αντι il-36r αντισωματα | |
| MX2016013372A (es) | Metodos de tratar selectivamente el asma utilizando antagonistas de il-13. | |
| WO2013158821A3 (en) | Methods of treating ankylosing spondylitis using il-17 antagonists | |
| MX353143B (es) | Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b. | |
| CA2813849C (en) | Secukinumab for use in the treatment of ankylosing spondylitis | |
| EP4374919A3 (en) | Methods for treating atopic dermatitis by administering an il-4r antagonist | |
| PH12013501490A1 (en) | Methods for diagnosing and treating eye-length related disorders | |
| UA116873C2 (uk) | Антитіло, яке зв'язується з ox40 | |
| WO2011154139A3 (en) | Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment | |
| MX2021015309A (es) | Composiciones para el tratamiento de la artritis reumatoide y metodos para su uso. | |
| NZ707139A (en) | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level | |
| BR112013021863A2 (pt) | anticorpos anti-receptor il-6 e métodos de uso | |
| EA201300978A1 (ru) | Антитела к сеа | |
| TW201613637A (en) | Methods of treating Alzheimer's Disease | |
| PH12014501164A1 (en) | Anti-cd98 antibodies and methods of use thereof | |
| MX2012008740A (es) | Metodos de tratamiento de enfermedades autoinmunes con antagonistas de ligando tipo delta 4. | |
| JO3766B1 (ar) | منشط مستقبل أسيتيل كولين الفا - 7 النيكوتيني | |
| UA96141C2 (ru) | Нейтрализующее антитело, которое имеет специфичность к человеческому il-6 | |
| EP3988673A3 (en) | Variants of tnfsf15 and dcr3 associated with crohn's disease | |
| EA201301107A1 (ru) | Моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
| EA201290360A1 (ru) | Гуманизированные антитела против il-22ra человека | |
| GB201109238D0 (en) | Antibodies | |
| WO2014155278A3 (en) | Methods of treating autoimmune diseases using il-17 antagonists |